Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19).
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
accepted:
17
11
2021
pubmed:
4
12
2021
medline:
15
12
2021
entrez:
3
12
2021
Statut:
ppublish
Résumé
Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients. We aimed to retrospectively evaluate the safety of remdesivir in older patients with COVID-19 who required hospitalization in our institute. We reviewed patients with COVID-19 who were treated with remdesivir at our institute between July 2020 and May 2021. We defined older patients as those aged 80 years or older at admission; all other patients were defined as younger patients. We evaluated the safety of remdesivir by examining the incidence of discontinuation of remdesivir treatment because of adverse events and the incidence of any adverse events. A total of 80 patients were included in this study. Compared with younger patients, fewer older patients were treated with remdesivir for more than 5 days: 4 (15.4%) vs 23 (42.6%). Discontinuation of remdesivir because of adverse events occurred in one older patient (3.9%) and four younger patients (7.4%) [p > 0.99]. Remdesivir-induced liver dysfunction was the most frequent adverse event, which occurred in 29 (36.3%) patients. There were no significant differences in the incidence of remdesivir-induced liver dysfunction, renal dysfunction, and fatigue. The safety of remdesivir was suggested to be comparable between patients older than 80 years of age and patients younger than 80 years of age. The results of this study may encourage the administration of remdesivir to this older patient group.
Sections du résumé
BACKGROUND AND OBJECTIVE
Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients. We aimed to retrospectively evaluate the safety of remdesivir in older patients with COVID-19 who required hospitalization in our institute.
METHODS
We reviewed patients with COVID-19 who were treated with remdesivir at our institute between July 2020 and May 2021. We defined older patients as those aged 80 years or older at admission; all other patients were defined as younger patients. We evaluated the safety of remdesivir by examining the incidence of discontinuation of remdesivir treatment because of adverse events and the incidence of any adverse events.
RESULTS
A total of 80 patients were included in this study. Compared with younger patients, fewer older patients were treated with remdesivir for more than 5 days: 4 (15.4%) vs 23 (42.6%). Discontinuation of remdesivir because of adverse events occurred in one older patient (3.9%) and four younger patients (7.4%) [p > 0.99]. Remdesivir-induced liver dysfunction was the most frequent adverse event, which occurred in 29 (36.3%) patients. There were no significant differences in the incidence of remdesivir-induced liver dysfunction, renal dysfunction, and fatigue.
CONCLUSIONS
The safety of remdesivir was suggested to be comparable between patients older than 80 years of age and patients younger than 80 years of age. The results of this study may encourage the administration of remdesivir to this older patient group.
Identifiants
pubmed: 34859387
doi: 10.1007/s40266-021-00908-9
pii: 10.1007/s40266-021-00908-9
pmc: PMC8638643
doi:
Substances chimiques
Antiviral Agents
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067-1074Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Front Med (Lausanne). 2021 Nov 18;8:767110
pubmed: 34869479
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Eur Respir J. 2020 Dec 24;56(6):
pubmed: 32943404
Int J Chron Obstruct Pulmon Dis. 2017 Aug 21;12:2465-2475
pubmed: 28860741
Lancet Respir Med. 2021 Dec;9(12):1407-1418
pubmed: 34480861
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088